MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

Trial Details

NCT ID

NCT06586515

Phase

PHASE1

Sponsor

Eli Lilly and Company

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

LY3962673
Cetuximab
Gemcitabine
nab-paclitaxel
Oxaliplatin
leucovorin

Locations (sample)

Duarte, California, United States|34.13945,-117.97729
Denver, Colorado, United States|39.73915,-104.9847
Washington D.C., District of Columbia, United States|38.89511,-77.03637
Orlando, Florida, United States|28.53834,-81.37924
Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

Have Histological or cytologically proven diagnosis of locally advanced, unresectable, and/or metastatic cancer and measurable disease per Response…
Have evidence of KRAS G12D mutation in tumor tissue or circulating tumor DNA
Have an ECOG performance status of ≤ 1
Must have received ≥ 1 prior line of systemic chemotherapy for advanced or metastatic disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →